EIF4E Human

Eukaryotic Translation Initiation Factor 4E Human Recombinant
Cat. No.
BT4932
Source
Escherichia Coli.
Synonyms
CBP, EIF4E1, EIF4EL1, EIF4F.
Appearance
Sterile filtered colorless solution.
Purity
Greater than 85.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

EIF4E Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 237 amino acids (1-217 a.a.) and having a molecular weight of 27.2kDa. The EIF4E is fused to a 20 aa His-Tag at N-terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
EIF4E, a member of the eukaryotic initiation factor 4 family, plays a crucial role in regulating the translation of maternal mRNAs during early embryonic development before zygotic transcription begins. This factor specifically recognizes and binds to the 7-methylguanosine (m7G) cap structure present at the 5' end of eukaryotic mRNAs. This interaction is essential for initiating translation as it facilitates the recruitment of ribosomes to the mRNA and aids in unwinding its secondary structures, allowing for efficient translation.
Description
Recombinant human EIF4E, expressed in E. coli, is a purified protein with a molecular weight of 27.2 kDa. It consists of a single polypeptide chain of 237 amino acids (residues 1-217), excluding any glycosylation modifications. A 20-amino acid Histidine tag is fused to the N-terminus to facilitate purification, which is achieved using proprietary chromatographic methods.
Physical Appearance
The product is a clear, colorless solution that has been sterilized through filtration.
Formulation
The EIF4E protein is supplied at a concentration of 0.5 mg/ml in a buffer consisting of 20 mM Tris-HCl (pH 8.0) and 10% glycerol.
Stability
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. Adding a carrier protein like HSA or BSA (0.1%) is advisable for long-term storage to maintain protein stability. Repeated freezing and thawing of the product should be avoided.
Purity
The purity of the EIF4E protein is greater than 85%, as determined by SDS-PAGE analysis.
Synonyms
CBP, EIF4E1, EIF4EL1, EIF4F.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MATVEPETTP TPNPPTTEEE KTESNQEVAN PEHYIKHPLQ NRWALWFFKN DKSKTWQANL RLISKFDTVE
DFWALYNHIQ LSSNLMPGCD YSLFKDGIEP MWEDEKNKRG GRWLITLNKQ QRRSDLDRFW LETLLCLIGE SFDDYSDDVC GAVVNVRAKG
DKIAIWTTEC ENREAVTHIG RVYKERLGLP PKIVIGYQSH ADTATKSGST TKNRFVV.

Product Science Overview

Introduction

Eukaryotic Translation Initiation Factor 4E (eIF4E) is a crucial protein involved in the initiation of translation in eukaryotic cells. It is a part of the eIF4F complex, which plays a pivotal role in the recognition of the 5’ cap structure of messenger RNAs (mRNAs) and the recruitment of ribosomes to initiate protein synthesis . The human recombinant form of eIF4E is produced using recombinant DNA technology, allowing for its use in various research and therapeutic applications.

Structure and Function

eIF4E is a cap-binding protein that specifically recognizes and binds to the 7-methylguanosine (m7G) cap at the 5’ end of eukaryotic mRNAs . This binding is essential for the recruitment of the eIF4F complex, which includes eIF4A (a helicase) and eIF4G (a scaffolding protein) . The eIF4F complex facilitates the unwinding of secondary structures in the 5’ untranslated region (UTR) of the mRNA, allowing the ribosome to access the mRNA and initiate translation .

Biological Significance

eIF4E is a rate-limiting factor in cap-dependent translation, meaning its availability and activity directly influence the efficiency of protein synthesis . It is involved in various cellular processes, including cell growth, proliferation, and survival . Dysregulation of eIF4E has been implicated in several diseases, including cancer, where its overexpression is often associated with tumorigenesis and poor prognosis .

Recombinant Production

The human recombinant form of eIF4E is produced using recombinant DNA technology, typically in bacterial or yeast expression systems . This involves cloning the eIF4E gene into an expression vector, transforming the host cells, and inducing protein expression. The recombinant protein is then purified using affinity chromatography techniques, such as His-tag or GST-tag purification .

Applications

Recombinant eIF4E is widely used in research to study the mechanisms of translation initiation and its regulation . It is also used in drug discovery and development, particularly in the search for inhibitors that can modulate eIF4E activity for therapeutic purposes . Additionally, recombinant eIF4E can be used in structural biology studies to elucidate its interactions with other components of the translation machinery .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.